Predictive value of interim ¹⁸F-FDG-PET/CT for event-free survival in patients with diffuse large B-cell lymphoma homogenously treated in a phase II trial with six cycles of R-CHOP-14 plus pegfilgrastim as first-line treatment
| Autor: | Eva, González-Barca, Miguel, Canales, Montse, Cortés, M Jesus, Vidal, Antonio, Salar, Albert, Oriol, Joan, Bargay, José L, Bello, José J, Sánchez, José F, Tomás, Eva, Donato, Secundino, Ferrer, Dolores, Caballero |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Adolescent Filgrastim Multimodal Imaging Disease-Free Survival Polyethylene Glycols Antibodies Monoclonal Murine-Derived Young Adult Fluorodeoxyglucose F18 Predictive Value of Tests Recurrence Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor Humans Treatment Failure Cyclophosphamide Aged Middle Aged Recombinant Proteins Doxorubicin Vincristine Positron-Emission Tomography Prednisone Female Lymphoma Large B-Cell Diffuse Rituximab Tomography X-Ray Computed |
| Zdroj: | Nuclear medicine communications. 34(10) |
| ISSN: | 1473-5628 |
| Popis: | The predictive value of interim PET/computed tomography (I-PET/CT) in diffuse large B-cell lymphoma (DLBCL) is controversial. Our aim was to evaluate the predictive value of I-PET/CT for an event-free survival.We analyzed patients with DLBCL included in a prospective clinical trial who were treated with six cycles of dose-dense R-CHOP followed by pegfilgrastim and who had undergone an I-PET/CT (after two cycles) and a final PET [F-PET/CT (60 days after the sixth cycle)]. Event was defined as nonresponse, relapse, or death.A total of 69 patients were included. Their median age was 60 years; 54% were male, 25% had bulky disease, and 67% had an International Prognostic Index of 0-2. The median follow-up duration was 28.8 months. I-PET/CT was positive in 34 (49%) patients and F-PET/CT was positive in 12 (17.4%). The 3-year event-free survival was 86% for patients who were I-PET/CT negative as against 64% for those who were I-PET/CT positive (P=0.036). The negative and positive predictive values, sensitivity, and specificity of I-PET/CT for an event were 83, 32, 65, and 56%, respectively. In a multivariate analysis including baseline characteristics, I-PET/CT, and F-PET/CT, F-PET/CT was the only significant predictor (P0.0005).In patients with DLBCL treated with dose-dense R-CHOP plus pegfilgrastim, a negative I-PET/CT is highly predictive of a favorable outcome and a positive I-PET/CT is of limited clinical value. These results do not support treatment intensification after a short course of chemotherapy based solely on a positive I-PET/CT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|